Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.
1. A composition comprising:
0.5 wt % to 50 wt %, based on total weight of the composition, of particles comprising a pharmaceutical active agent, the particles having a median particle size, as measured by laser diffraction, ranging from 0.1 micrometer to 100 micrometers;
10 wt % to 60 wt %, based on total weight of the composition, of sucrose acetate isobutyrate;
1 wt % to 30 wt %, based on total weight of the composition, of a lactic acid-based polymer comprising an alkoxy end group having 8 to 24 carbons, the lactic acid-based polymer having a lactic acid to glycolic acid molar ratio ranging from 100:0 to 40:60, the lactic acid-based polymer having a weight average molecular weight ranging from 4000 Daltons to 30,000 Daltons; and
10 wt % to 50 wt %, based on total weight of the composition, of an organic solvent comprising at least one member selected from N-methyl-pyrrolidone, dimethylsulfoxide, propylene carbonate, and benzyl benzoate.
2. The composition of claim 1 , wherein the pharmaceutical active agent comprises at least one member selected from peptide, protein, and small molecule.
3. The composition of claim 1 , wherein the particles have a median particle size, as measured by laser diffraction, ranging from 0.2 micrometer to 50 micrometers.
4. The composition of claim 2 , wherein the particles have a median particle size, as measured by laser diffraction, ranging from 0.2 micrometer to 50 micrometers.
5. The composition of claim 1 , wherein the particles have a median particle size, as measured by laser diffraction, ranging from 0.25 micrometer to 50 micrometers.
6. The composition of claim 2 , wherein the particles have a median particle size, as measured by laser diffraction, ranging from 0.25 micrometer to 50 micrometers.
7. The composition of claim 1 , wherein the sucrose acetate isobutyrate is present in the composition in an amount ranging from 10 wt % to 25 wt %, based on total weight of the composition.
8. The composition of claim 1 , wherein the lactic acid-based polymer has a lactic acid to glycolic acid molar ratio ranging from 95:5 to 60:40.
9. The composition of claim 1 , wherein the lactic acid-based polymer has a weight average molecular weight ranging from 15,000 Daltons to 30,000 Daltons.
10. The composition of claim 1 , wherein the organic solvent comprises benzyl benzoate.
11. The composition of claim 1 , wherein the organic solvent comprises at least one of N-methyl-pyrrolidone, dimethylsulfoxide, and propylene carbonate.
12. The composition of claim 1 , wherein a weight ratio of the sucrose acetate isobutyrate to the lactic acid-based polymer to the organic solvent ranges from 1:0.066-1.3:0.3-1.7.
13. The composition of claim 1 , wherein when the composition is administered subcutaneously as a single dose to a human patient, a median amount of pharmaceutical active agent released from the composition provides an AUC(0 to 1 day) that is less than 20% of AUC(0 to 28 days).
14. The composition of claim 2 , wherein when the composition is administered subcutaneously as a single dose to a human patient, a median amount of pharmaceutical active agent released from the composition provides an AUC(0 to 1 day) that is less than 20% of AUC(0 to 28 days).
15. The composition of claim 8 , wherein when the composition is administered subcutaneously as a single dose to a human patient, a median amount of pharmaceutical active agent released from the composition provides an AUC(0 to 1 day) that is less than 20% of AUC(0 to 28 days).
16. The composition of claim 1 , wherein the composition has a viscosity of less than 3000 cP at a shear rate of 100 s −1 at 25° C.
17. The composition of claim 2 , wherein the composition has a viscosity of less than 3000 cP at a shear rate of 100 s −1 at 25° C.
18. The composition of claim 5 , wherein the composition has a viscosity of less than 3000 cP at a shear rate of 100 s −1 at 25° C.
19. The composition of claim 6 , wherein the composition has a viscosity of less than 3000 cP at a shear rate of 100 s −1 at 25° C.
20. The composition of claim 13 , wherein the composition has a viscosity of less than 3000 cP at a shear rate of 100 s −1 at 25° C.